Citi maintains 'sell' on Haleon, cuts target price on FX optimism and US channel concerns

Citi reiterated a 'sell' on Haleon and trimmed its price target to 335p from 340p, despite shares trading at 377.20p, warning that FX-driven share gains mask structural weaknesses. The bank highlighted FX tailwinds from emerging-market currencies (notably the rouble and rand), noted Russia accounts for ~3–4% of group EBIT and that a 20% rouble appreciation would add ~10bps to margins, but flagged US channel shift, weakening cold-and-flu trends and slowing online search for powerbrands. Citi cut EPS forecasts by 0.7% for 2025 and 1.8% for 2026 (with its 2026 view ~3.9% below consensus), implying continued downside risk to Haleon’s earnings momentum and valuation.

Analysis

Market structure: FX tailwinds (notably a 20% rouble move = ~10bp to group margins) are a short-lived plug that benefits reported EPS and EM-exposed peers, while the real losers are incumbents with weak direct-to-consumer capabilities—Haleon (HLN) sits squarely in that bucket given Citi's note on US channel shift and falling search momentum. Slowing cold & flu demand signals softer unit volumes, ceding pricing power to private labels and digital-native challengers; expect downward pressure on top-line growth and mix over the next 3–12 months.

Risk assessment: Near-term (days–weeks) upside rallies will be FX-driven and vulnerable to currency reversals; medium-term (3–6 months) risks center on retail channel data and Q1 organic sales misses, while long-term (12–24 months) structural channel shift could trim EBIT margins by 100–300bps. Tail risks include a faster-than-expected private-label takeover in the US (EPS shock -5–10% consensus) or an activist/bid event that would re-rate the stock higher; hidden dependencies include shelf-spacing contracts and retailer inventory digestion that can amplify variability.

Trade implications: Tactical short exposure to HLN is attractive: the market has priced-in transient FX gains (current 377.2p vs Citi PT 335p = ~11% downside). Implement size-controlled positions (2–3% portfolio) or 6–9 month put spreads (e.g., 370p/320p) to limit capital, and pair-short HLN vs long PG or JNJ to isolate channel risk. Options: buy 6–9 month puts or put spreads to express downside; avoid naked short gamma—use defined-risk spreads and scale in over 2–6 weeks as FX noise fades.

Contrarian angles: Consensus underestimates persistence of channel shift and overestimates value of EM FX tailwinds—this rally looks overstretched unless FX continues for multiple quarters. However, takeover/activist scenarios and durable cost savings could surprise to the upside; therefore caps on position size and use of asymmetrical option structures are critical to avoid squeeze or event-driven losses.

Key Decisions for Investors

• Establish a 2–3% portfolio short position in HLN (LSE:HLN) targeting 335p within 3–6 months; set a tactical stop-loss at 405p (~+7% from 377.2p) and scale into the short over 2–4 weeks as FX-driven volatility cools.
• Buy a 6–9 month HLN put spread sized to 1% of portfolio: long 370p / short 320p (pence strikes) to express downside to ~320p with defined risk and positive carry if search/sales continue to decelerate; roll or add if Q1 organic sales miss consensus by >3% y/y.
• Execute a pair trade: short HLN (size A) and go long Procter & Gamble (PG) or Johnson & Johnson (JNJ) (size A) to neutralize broad consumer-staples beta and isolate channel disruption risk; rebalance after Q1 results or if HLN EPS revisions exceed -5% consensus.
• Reduce exposure to pure-play consumer-health equities lacking DTC/e-commerce strength by 50% (relative to benchmark) and reallocate to diversified staples (PG, JNJ) and select e-commerce-enabled OTC brands; reassess after 90 days or upon a sustained >10% reversal in emerging-market FX supportive moves.